1. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas
- Author
-
Ren, Yuan, Bi, Chengfeng, Zhao, Xiaohong, Lwin, Tint, Wang, Cheng, Yuan, Ji, Silva, Ariosto S., Shah, Bijal D., Fang, Bin, Li, Tao, Koomen, John M., Jiang, Huijuan, Chavez, Julio C., Pham, Lan V., Sudalagunta, Praneeth R., Wan, Lixin, Wang, Xuefeng, Dalton, William S., Moscinski, Lynn C., Shain, Kenneth H., Vose, Julie, Cleveland, John L., Sotomayor, Eduardo M., Fu, Kai, and Tao, Jianguo
- Subjects
Gene expression -- Research ,Lymphocytic leukemia -- Care and treatment -- Genetic aspects -- Patient outcomes ,Health care industry - Abstract
Concordant activation of MYC and BCL-2 oncoproteins in double-hit lymphoma (DHL) results in aggressive disease that is refractory to treatment. By integrating activity-based proteomic profiling and drug screens, polo-like kinase-1 (PLK1) was identified as an essential regulator of the MYC-dependent kinome in DHL. Notably, PLK1 was expressed at high levels in DHL, correlated with MYC expression, and connoted poor outcome. Further, PLK1 signaling augmented MYC protein stability, and in turn, MYC directly induced PLK1 transcription, establishing a feed-forward MYC-PLK1 circuit in DHL. Finally, inhibition of PLK1 triggered degradation of MYC and of the antiapoptotic protein MCL-1, and PLK1 inhibitors showed synergy with BCL-2 antagonists in blocking DHL cell growth, survival, and tumorigenicity, supporting clinical targeting of PLK1 in DHL., Introduction MYC is a transcription factor that promotes oncogenesis by activating and repressing target genes that control cell growth, metabolism, and division (1, 2). MYC is deregulated in a large [...]
- Published
- 2018
- Full Text
- View/download PDF